Nicotine Addiction Drug Pipeline Report 2024: Comprehensive Insights on 15+ Companies and 15+ Pipeline Drugs

Dublin, April 11, 2024 (GLOBE NEWSWIRE) -- The "Nicotine Addiction - Pipeline Insight, 2024" clinical trials has been added to's offering.

This "Nicotine Addiction - Pipeline Insight, 2024," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Nicotine Addiction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nicotine Addiction pipeline landscape is provided which includes the disease overview and Nicotine Addiction treatment guidelines. The assessment part of the report embraces, in depth Nicotine Addiction commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Nicotine Addiction Emerging Drugs

EMB-001: Embera Neuro Therapeutics EMB-001 is a patented combination product comprised of two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiological responses to stress in addiction.

NFL-101: NFL BiosciencesNFL-101 is a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. NFL-101 is a natural product based on a standardized extract of tobacco leaf. NFL-101 is delivered via two simple subcutaneous injections, administered one week apart at a Target Quit Date, making patient compliance a breeze. Two additional, optional injections are made available to patients still not abstinent at month three and six.

Nicotine Addiction: Therapeutic Assessment

This segment of the report provides insights about the different Nicotine Addiction drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nicotine Addiction

There are approx. 15+ key companies which are developing the therapies for Nicotine Addiction. The companies which have their Nicotine Addiction drug candidates in the most advanced stage, i.e. Phase III include Achieve Life Sciences.

Nicotine Addiction: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nicotine Addiction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nicotine Addiction drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence in Nicotine Addiction R&D. The therapies under development are focused on novel approaches to treat/improve in Nicotine Addiction.
  • In June 2021, The PEC-Direct Phase 2 study enrolled additional patients to evaluate the safety and efficacy of PEC-Direct implanted subcutaneously in patients with T1D who have Nicotine Addiction unawareness and/or extreme glycemic lability. Study participants upon enrollment are required to be negative for C-peptide, which is not confounded by exogenous insulin. The Company anticipates reporting additional patient data readouts from the PEC-Direct study in the first half of 2022.
  • This segment of the Nicotine Addiction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Key Players

  • CTC Bio
  • Omeros
  • Antidote Therapeutics
  • Achieve Life Sciences
  • Respira Technologies
  • Mydecine
  • Astraea Therapeutics
  • Cessation Therapeutics
  • Alex Therapeutics
  • Embera Neuro Therapeutics
  • Novo Nordisk
  • Axsome Therapeutics

Key Products

  • Varenicline
  • OMS405
  • ATI-1013
  • Cytisinicline
  • Nicotine addiction research project
  • Psilocybin
  • Nicotine addiction Astraea research project
  • NicA2 Research Project
  • EMB-001
  • Eila
  • Liraglutide PII
  • Bupropion/dextromethorphan


  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

Molecule Type

  • Small molecule
  • Peptides

Nicotine Addiction Report Insights

  • Nicotine Addiction Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Nicotine Addiction Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data